Comparative Pharmacology
Head-to-head clinical analysis: MD 76R versus RENORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76R versus RENORMAX.
MD-76R vs RENORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
Selective beta-1 adrenergic receptor antagonist; reduces cardiac output, heart rate, and blood pressure by blocking catecholamine effects on cardiac beta-1 receptors.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
5 mg intravenously every 12 hours
None Documented
None Documented
Terminal half-life 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life: 8-10 hours in healthy adults. Prolonged to 18-24 hours in moderate renal impairment (CrCl 30-50 mL/min). Provides basis for twice-daily dosing in normal renal function.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Primarily renal (60-70% unchanged; 10-15% as glucuronide conjugate); biliary/fecal (5-10%); 80-85% total recovered in urine and feces within 72 hours.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent